ReviewJournal of orthopaedics2025
Meta-analysis of 65 Adamantinoma case reports: Unveiling symptomatology, demographics, and treatment outcomes in contrast to prior understandings.
Review in Journal of orthopaedics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Imaging Analysis for Metastatic Risk Assessment in Adamantinoma: The Aid of Radiology in the Absence of a Histological Grading-An MRI-Based Risk Model Proposal.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adamantinomas are rare, malignant bone tumors predominantly affecting the tibia. This study compares demographics, clinical presentations, radiographic findings, metastasis rates, and treatment outcomes of adamantinoma cases from a contemporary review of 65 cases with a historical review by Keeney et al. (1989). Our data reveals a significant increase in the average age at diagnosis, from 25.9 years in the prior study to 38.1 years in the new study, with notable increases for both males and females. The metastasis rate in our study was 45.3 %, significantly higher than the 23.5 % reported previously with a wider range of possible sites. Treatment options have changed with significant improvement in survivability and remission with allograft and endoprosthesis techniques compared to older techniques of amputation and resection. This study highlights the evolving understanding of adamantinoma, emphasizing the changes in presentation and the effectiveness of advanced surgical treatments.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.